NDAORALTABLETPriority Review
Approved
Nov 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Clinical Trials (5)
HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Started Oct 2026
42 enrolled
Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory+2 more
Rash & Diarrhea Prophylaxis With Capivasertib
Started Apr 2026
108 enrolled
Metastatic HR+/HER2- Breast Cancer
A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants
Started Jan 2026
35 enrolled
Healthy Participants
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
Started Jan 2026
20 enrolled
Moderate Hepatic Impairment
Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
Started Nov 2025
250 enrolled
Breast CancerHR-positive Breast CancerAdvanced Breast Cancer+2 more
Loss of Exclusivity
LOE Date
Apr 16, 2033
86 months away
Patent Expiry
Apr 16, 2033
Exclusivity Expiry
Nov 16, 2028